133 related articles for article (PubMed ID: 17169217)
1. Open conflict on the handling of the Merck drug Vioxx by editorial giants.
Edwards RG
Reprod Biomed Online; 2006 Dec; 13(6):905. PubMed ID: 17169217
[No Abstract] [Full Text] [Related]
2. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Armstrong D
Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
[No Abstract] [Full Text] [Related]
3. What have we learnt from Vioxx?
Krumholz HM; Ross JS; Presler AH; Egilman DS
BMJ; 2007 Jan; 334(7585):120-3. PubMed ID: 17235089
[TBL] [Abstract][Full Text] [Related]
4. Medical journal criticizes Merck over Vioxx data.
Berenson A
N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
[No Abstract] [Full Text] [Related]
5. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
Moynihan R
BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
[No Abstract] [Full Text] [Related]
6. Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld.
Couzin J
Science; 2005 Dec; 310(5755):1755. PubMed ID: 16357236
[No Abstract] [Full Text] [Related]
7. Quebec allows Vioxx class-action suit.
Sibbald B
CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
[No Abstract] [Full Text] [Related]
8. A message from the Vioxx case.
Baldwin HJ; Droege M; Daniel KL
Am J Health Syst Pharm; 2006 Mar; 63(6):503. PubMed ID: 16522877
[No Abstract] [Full Text] [Related]
9. Merck's actions surrounding Vioxx.
Heinley M
PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
[No Abstract] [Full Text] [Related]
10. Vioxx doctors wooed by Merck are now its foes.
Tesoriero HW
Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
[No Abstract] [Full Text] [Related]
11. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
Cahana A; Mauron A
J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
[No Abstract] [Full Text] [Related]
12. Manipulating a journal article.
N Y Times Web; 2005 Dec; ():WK11. PubMed ID: 16453395
[No Abstract] [Full Text] [Related]
13. 94% of patients suing Merck over rofecoxib agree to company's offer.
Charatan F
BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064
[No Abstract] [Full Text] [Related]
14. The lessons of Vioxx--drug safety and sales.
Waxman HA
N Engl J Med; 2005 Jun; 352(25):2576-8. PubMed ID: 15972862
[No Abstract] [Full Text] [Related]
15. Will Merck survive Vioxx?
Simons J; Stipp D
Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
[No Abstract] [Full Text] [Related]
16. US judge dismisses 50m dollars damages in Vioxx lawsuit.
Charatan F
BMJ; 2006 Sep; 333(7567):516. PubMed ID: 16960199
[No Abstract] [Full Text] [Related]
17. Merck to pay $5bn in rofecoxib claims.
Charatan F
BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
[No Abstract] [Full Text] [Related]
18. Merck Sharpe and Dohme versus Laporte.
Laporte JR
Lancet; 2004 Jul 31-Aug 6; 364(9432):416. PubMed ID: 15288737
[No Abstract] [Full Text] [Related]
19. Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research.
Berger E
Ann Emerg Med; 2008 Aug; 52(2):137-9. PubMed ID: 18672488
[No Abstract] [Full Text] [Related]
20. Merck's Careful Study of Vioxx.
Mayer TV
Am J Cardiol; 2008 Apr; 101(7):1068-9; author reply 1069. PubMed ID: 18359336
[No Abstract] [Full Text] [Related]
[Next] [New Search]
